Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 30.12.14 |
Itay Weinstein
DFI | Director of Finance/CFO | 52 | 01.01.99 |
Doron Turgeman
CHM | Chairman | 56 | 30.12.14 |
Daphna Paran
CTO | Chief Tech/Sci/R&D Officer | - | 04.03.16 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 30.12.14 |
Director/Board Member | 57 | 29.01.20 | |
Director/Board Member | 53 | 01.04.17 | |
Doron Turgeman
CHM | Chairman | 56 | 30.12.14 |
Director/Board Member | 46 | 08.12.14 | |
Director/Board Member | 57 | 01.03.15 | |
Director/Board Member | 63 | 08.12.14 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 514 205 799 | 479 737 353 ( 93,30 %) | 0 | 93,30 % |
Unternehmenskontakt
XTL Biopharmaceuticals Ltd.
26 Ben-Gurion Street
5112001, Ramat Gan
+972 3 611 6600
http://www.xtlbio.com![Straße Xtl Biopharma](https://cdn.zonebourse.com/static/address/10619579.png)
Sektor
% 1. Jan. | Kap. | |
---|---|---|
+25.83% | 46.56 Mrd. | |
+45.38% | 41.67 Mrd. | |
+0.69% | 41.16 Mrd. | |
+30.52% | 32.4 Mrd. | |
+22.30% | 28.18 Mrd. | |
-6.35% | 28.1 Mrd. | |
+49.25% | 14.52 Mrd. | |
+49.18% | 13.74 Mrd. | |
+3.45% | 12.17 Mrd. |